Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering

BERKELEY, CA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces it has elected not to proceed with its public offering and intends to file a post-effective amendment with the U.S. Securities and Exchange Commission (the “SEC”) for the Company’s Registration Statement on Form S-1 (No. 333-293451), as amended, originally filed with the SEC on February 13, 2026 (the “Registration Statement”). The Company will pursue a smaller, more focused offering to support near-term projected Europe Lumee

Oxygen product revenue starting in Q2 2026 and investment in its Mayo collaboration to accelerate Lumee Oxygen in the U.S. and develop and commercialize new continuous oxygen monitoring products. No securities were sold in connection with the offering described in the Registration Statement.

“We determined that due to our recently announced commercial and operational progress, a smaller, more focused offering is better aligned with our current operational requirements and in the best interest of the Company and its shareholders. Our decision reflects our continued progress in strengthening our balance sheet; having made important operational progress with commercial operations in anticipation of our projected early Q2 2026 Europe Oxygen market launch; and our targeted U.S. market entry for Lumee Oxygen in late 2026 in collaboration with the Mayo Clinic,” said Ben Hwang, Ph.D., Profusa’s Chairman and CEO.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Company’s common stock or any securities, and there shall not be any offer, solicitation or sale of securities mentioned in the press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of such any state or jurisdiction.

Based in Berkeley, CA, Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.

“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa, Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.